(19)
(11) EP 3 271 335 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
27.03.2019 Bulletin 2019/13

(45) Mention of the grant of the patent:
26.12.2018 Bulletin 2018/52

(21) Application number: 16710161.7

(22) Date of filing: 16.03.2016
(51) International Patent Classification (IPC): 
C07D 219/12(2006.01)
A61P 25/28(2006.01)
 A61K 31/435(2006.01)
(86) International application number:
PCT/EP2016/055633
(87) International publication number:
WO 2016/146655 (22.09.2016 Gazette 2016/38)

(54)

NOVEL 1,4-BIS(3-AMINOPROPYL)PIPERAZINE DERIVATIVE AND ITS USE

1,4-BIS(3-AMINOPROPYL)PIPERAZIN-DERIVATE UND DEREN VERWENDUNG

DÉRIVÉ DE 1,4-BIS (3-AMINOPROPYL)PIPÉRAZINE ET UTILISATION DE CELUI-CI

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.03.2015 EP 15305384

(43) Date of publication of application:
24.01.2018 Bulletin 2018/04

(73) Proprietors:
  • INSERM (Institut National de la Santé et de la Recherche Médicale)
    75013 Paris (FR)
  • Centre Hospitalier Régional et Universitaire de Lille (CHRU)
    59000 Lille (FR)
  • Université de Lille
    59800 Lille (FR)

(72) Inventors:
  • SERGEANT, Nicolas
    59045 Lille Cedex (FR)
  • BUEE, Luc
    59045 Lille Cedex (FR)
  • MELNYK, Patricia
    59000 Lille (FR)
  • GAY, Marion
    59000 Lille (FR)
  • LE FUR, Nicolas
    59100 Roubaix (FR)

(74) Representative: Cabinet Plasseraud 
31, rue des Poissonceaux CS 40009
59044 Lille Cedex
59044 Lille Cedex (FR)


(56) References cited: : 
WO-A1-2006/051489
   
  • PATRICIA MELNYK ET AL: "Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism", ACS CHEMICAL NEUROSCIENCE, vol. 6, no. 4, 22 February 2015 (2015-02-22), pages 559-569, XP055197273, ISSN: 1948-7193, DOI: 10.1021/cn5003013
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).